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3020Objective:Aortoesophageal and aortobronchial fistulas are uncommon but life-threatening conditions. The pre-
sent study aimed to identify potential differences in outcomes, depending on the etiology, type, and management
of the fistulas, and to determine mortality predictors.
Methods:We retrospectively reviewed a series of 26 consecutive patients with thoracic aorta fistulas admitted to
our institution from 1998 to 2013 (18 aortobronchial, 7 aortoesophageal, and 1 combined fistula).
Results: The mean age was 61.5  13.4 years, with 22 men. Management was thoracic endovascular aortic
repair (TEVAR) in 8, open repair in 7, and conservative in 11. The TEVAR and nonoperative patients were
significantly older and presented with more comorbidities. Shock developed in 15 patients and sepsis in 9.
The most common radiologic findings were intramural hematoma (65.4%), pseudoaneurysm (53.8%), and
bronchial compression (46.20%). Active contrast extravasation (23.1%) and ectopic gas (19.2%) were associ-
ated with a worse prognosis. In-hospital mortality was 100% in the conservative group, 37.5% in the TEVAR
group, and 14.3% in the open repair group (P ¼ .04). Septic shock was the most common cause of death. The
risk factors for in-hospital mortality were hemodynamic instability on admission (P¼ .02), sepsis (P¼ .04), and
conservative management (P<.001). The overall long-term survival in surgical patients at 1 and 5 years was
66% and 58.7%, respectively. Infectious and malignant etiologies resulted in the worst prognosis.
Conclusions: The outcomes are ultimately conditioned by the etiology of the fistula. Both open and endovas-
cular management of aortic fistulas can prevent death by exsanguination; however, patients remain at high risk of
infectious complications. Failure to treat the underlying cause will result in poor midterm outcomes. (J Thorac
Cardiovasc Surg 2014;148:3020-6)Supplemental material is available online.
Aortoesophageal (AEF) and aortobronchial (ABF) fistulas
pose one of the most vexing and challenging surgical prob-
lems to manage. Both types of thoracic aorta fistulas are un-
common, but life-threatening conditions if left untreated.
Primary AEFs and ABFs are most commonly found in asso-
ciation with aortic aneurysms, ruptured penetrating aortic
ulcers, thoracic trauma, ingestion of foreign bodies, and
esophageal or bronchogenic malignancies. Secondary fis-
tulas are potential complications of either open1 or endovas-
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The Journal of Thoracic and Cardiovascular SurThe classic management of ABFs and AEFs has been
open surgical repair. Nonetheless, single center series5-7
and multicenter studies8,9 describing the successful
management of both AEFs and ABFs using thoracic
endovascular aortic repair (TEVAR) have been published
during the past 10 years. Both open and endovascular
surgical treatment can prevent patient death by
exsanguination; however, patients remain at high risk of
infectious complications. Neither the bronchi nor the
esophagus are sterile cavities; therefore, the risk of
infectious complications is significantly increased if the
bronchial or esophageal defect is not repaired. This is of
utmost importance when managing aortic fistulas caused
by mycotic pseudoaneurysms or malignancy.
Furthermore, addressing the underlying pathologic entity
is crucial when considering the mid- and long-term out-
comes of the fistulas.
The aim of the present study was to identify potential dif-
ferences in early- and long-term results, stratified by the eti-
ology, type, and management of the fistulas, and to
determine the mortality predictors in this critical subset of
patients. We also report the clinical and radiologic charac-
teristics, treatment, and outcomes of a consistent series of
patients with AEFs and ABFs.gery c December 2014
Abbreviations and Acronyms
ABF ¼ aortobronchial fistula
AEF ¼ aortoesophageal fistula
CT ¼ computed tomography
TEVAR ¼ thoracic endovascular aortic repair
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This was an historic cohort study enrolling a total of 26 patients with
thoracic aorta fistulas admitted to our institution from January 1998 to
October 2013. The thoracic aorta fistulas involved the left bronchial tree
in 18 patients and the esophagus in 8, including 1 patient with a combined
AEF and ABF.
Hemodynamic instability on admission was defined as a systolic blood
pressure of<90 mm Hg or the need for fluid and/or inotropic support to
maintain a blood pressure of 90 mm Hg.
Urgency of the surgical procedure was classified as elective, when per-
formed during a routine admission for surgery; urgent for patients not elec-
tively admitted for surgery but who required surgery on that admission for
medical reasons; and emergency, when surgery was performed before the
beginning of the next working day after a decision had been made to
operate.
The study adhered to the STrengthening the Reporting of OBservational
studies in Epidemiology (STROBE) initiative.10 The institutional review
board approved the present study for retrospective data retrieval, waiving
the requirement for individual patient consent.
Imaging Evaluation
All the patients, except for 1, had 1 computed tomography (CT) scan
performed at admission. The diagnosis was determined from the CT scan
data but also using the findings from other imaging techniques (eg, angiog-
raphy, transesophageal echocardiography, and gastrointestinal or bronchial
endoscopy). When available, confirmation was provided by surgical visu-
alization and/or autopsy. No disagreement was found in the data provided
by the imaging studies.
The identification of active extravasation was defined as the only defin-
itive CT scan finding of ABF or AEF. Secondary signs helped us predict the
high likelihood of the diagnosis. However, they could also be seen in the
presence of graft infection or inflammation without ABF or AEF. These
signs included the presence of periaortic (ectopic) gas, an aortic pseudoa-
neurysm bulge, a penetrating atherosclerotic ulcer, an intramural hema-
toma, effacement of the periaortic or perigraft fat plane, esophageal wall
thickening, and a periprosthetic collection.11-14Surgical Treatment
In our series, open surgical management was selected for 7 patients. A
left posterolateral thoracotomywas performed in 5 and a thoracoabdominal
approach was required in 2 patients. Five patients underwent emergency
open surgical repair and two underwent urgent open repair.
A Dacron graft was used in 5 patients, and patch repair was performed in
2 patients. Left heart bypass was established in 5 patients, and cardiopul-
monary bypass was selected for 2 patients. Surgical repair of the broncho-
pulmonary end consisted of primary closure (n ¼ 4) or lobectomy (n ¼ 2).
In 1 case of AEF, the esophageal opening was repaired by primary closure
and was reinforced with a pericardial patch.
Direct contact between the vascular reconstruction and the pulmonary
or esophageal tissue was avoided to prevent additional erosive damage.
The repaired aorta was covered by the remains of either the pseudoaneur-
ysm wall (n ¼ 3) or the surrounding viable tissue (n ¼ 4).
Eight patients underwent TEVAR. Four TEVAR procedures were per-
formed on an emergency basis, and four on an urgent basis. EndovascularThe Journal of Thoracic and Carstent placement procedures were performed in the operating room with the
patients under general anesthesia.15 Access was by way of the right com-
mon femoral artery for all patients. Endovascular repair was performed
using the Talent thoracic stent-graft in 1 patient, the Valiant thoracic
stent-graft in 2 patients, and the Valiant Captivia thoracic stent-graft (Med-
tronic, Medtronic Vascular, Santa Rosa, Calif) in 5 patients. Two or more
stent-grafts were used to cover the lesion in 5 patients. No patient required
covering of the left subclavian artery. Adjunctive surgical procedures to
TEVAR in those with an ABF were 2 left lobectomies, 3 thoracic drainage
procedures, 1 bronchial stenting, and 1 surgery of a septic spondylodiscitis.
In the 2 cases of AEF, 1 patient also underwent esophagectomy and cervical
esophagostomy and had a feeding gastrostomy tube place, and the other pa-
tient underwent esophagectomy with reconstruction 1 week later.
The selection criteria were hemodynamic stability, comorbidities
affecting the patient’s life expectancy and quality of life, and factors deter-
mining technical feasibility (Online Data Supplement, ‘‘Selection
Criteria’’). Emergency TEVAR has been available at our institution since
January 2003 because of the need for an in-hospital stock of thoracic aortic
endografts (Figure E1 shows the modifications in patient management
since the incorporation of emergency TEVAR).
Statistical Analysis
Data are expressed as the mean  standard deviation or median and
range, as appropriate.16 For bivariate analysis, proportions were compared
using contingency tables and the chi-square test with Yates’ correction or
Fisher’s exact test. Student’s t test was used to compare continuous vari-
ables. Actuarial estimates of survival were accomplished using Kaplan-
Meier methods. Differences in survival between the groups were analyzed
using the log-rank test.
The Statistical Program for Social Sciences, for Windows, version 17.0
(SPSS, Chicago, Ill), was used for data analysis.RESULTS
Most of the patients were men (22 patients, 84.6%), with
a mean age of 61.5  13.4 years. The patients’ demo-
graphics and preoperative risk factors are listed in Table 1.
Overall, the most common cause of the aortic fistulas was
aortic atherosclerotic aneurysms (8 patients, 30.8%). In those
with ABFs, aortic aneurysms remained the most common
cause (6 patients, 33.3%); however, esophageal malignancy
(3 patients, 37.5%) was the most common cause of AEFs.
The mean aortic diameter was 68.4  19.4 mm (range,
32-100). No significant differences were found between
ABFs and AEFs in the mean aortic diameter (69.5  18.3
mm vs 65.9  22.7 mm; P ¼ .67). The thoracic descending
aorta was the most commonly affected aortic segment (22
cases, 84.6%), with the disease extending from the aortic
arch in only 2. The aortic disease was limited to the aortic
arch in 4 patients (15.3%), and the extension of the aortic
disease included the abdominal aorta in 5 patients (19.2%).
The symptoms at presentation are listed in Table 2. Of the
26 patients, 21 (80.8%) had experienced progressive he-
moptysis and/or hematemesis, and 15 (57.7%) had pre-
sented with hemodynamic instability on arrival at the
hospital or had developed it shortly after admission. Shock
was present in 10 patients (55.6%) with an ABF and in 5
patients (62.5%) with an AEF (P¼ .74). The blood cultures
were positive in 9 cases (34.6%) on admission. Isolateddiovascular Surgery c Volume 148, Number 6 3021
TABLE 1. Demographics and preoperative risk factors
Characteristic Overall ABF AEF P value
Age (y) 61.5  13.4 59.4  15.3 66.2  6.6 .23
Male gender 22 (84.6) 16 (88.9) 6 (75) .75
Obesity 7 (26.9) 5 (27.8) 2 (25) .88
Hypertension 17 (65.4) 12 (66.7) 6 (62.5) .84
Diabetes mellitus 3 (11.5) 1 (5.6) 2 (25) .44
Hypercholesterolemia 9 (34.6) 6 (33.3) 3 (37.5) .84
COPD 11 (42.3) 7 (38.9) 4 (50) .6
Renal failure 7 (26.9) 4 (22.2) 3 (37.5) .42
Peripheral arterial disease 9 (34.6) 5 (27.8) 4 (50) .27
Coronary artery disease 5 (19.2) 2 (11.1) 3 (37.5) .3
Cerebrovascular disease 2 (7.7) 2 (11.1) 0 .85
Previous cardiac surgery 10 (38.5) 8 (44.4) 2 (25) .34
Previous vascular surgery 7 (26.9) 4 (22.2) 3 (37.5) .42
ASA class III 26 (100) 18 (100) 8 (100) .99
Logistic EuroSCORE (%) 40.7  20.4 37.6  19.8 47.7  21.2 .25
Primary fistula 18 (69.2) 12 (66.7) 6 (75) .67
Etiology of fistula .13
Atherosclerotic aneurysm 8 (30.8) 6 (33.3) 2 (25)
Mycotic pseudoaneurysm 3 (11.5) 3 (16.6) 0
Post-traumatic
pseudoaneurysm
3 (11.5) 2 (11.1) 1 (12.5)
Esophageal cancer 3 (11.5) 0 3 (37.5)
Lung cancer 1 (3.8) 1 (5.6) 0
Secondary aortic open repair 6 (23.1) 5 (27.8) 1 (12.5)
Secondary TEVAR 2 (7.7) 1 (5.6) 1 (12.5)
Data presented as mean standard deviation or n (%). ABF, Aortobronchial fistula; AEF, aortoesophageal fistula;COPD, chronic obstructive pulmonary disease; ASA, American
Society of Anesthesiologists; TEVAR, thoracic endovascular aortic repair.
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E1. Sepsis tended to be more frequent among patients
with secondary fistulas, but this difference did not reach sta-
tistical significance (50% vs 27.8%, P ¼ .27). No statisti-
cally significant differences were found between those
with an ABF and those with an AEF (33.3% vs 37.5%,
P ¼ .99). The patients with sepsis experienced greater in-
hospital mortality (53.3% vs 9.1%, P ¼ .04).TABLE 2. Symptoms at presentation
Characteristic Overall (n) ABF (n) AEF (n) P value
Symptoms at presentation
Hematemesis or
hemoptysis
26 (100) 18 (100) 8 (100) .99
Hemothorax 10 (38.5) 7 (38.9) 3 (37.5) .99
Fever 10 (38.5) 7 (38.9) 3 (37.5) .94
Shock 15 (57.7) 10 (55.6) 5 (62.5) .74
Thoracic or back pain 17 (70.8) 11 (68.8) 6 (75) .99
Abdominal pain 3 (12.5) 0 3 (37.5) .03
Dyspnea 7 (26.9) 4 (22.2) 3 (37.5) .41
Dysphagia 8 (30.8) 3 (16.7) 5 (62.5) .06
Melena 2 (7.7) 0 2 (25) .16
Malaise or weight loss 10 (38.5) 7 (38.9) 3 (37.5) .99
Chronic anemia 6 (23.1) 3 (16.7) 3 (37.5) .51
Data in parentheses are percentages. ABF, Aortobronchial fistula; AEF, aortoesopha-
geal fistula.
3022 The Journal of Thoracic and Cardiovascular SurThe diagnostic test and CT scan findings are listed in
Table 3. The most common CT findings were, in descending
order of frequency, hemorrhage of the aortic wall or intra-
mural hematoma (17 patients, 65.4%), aortic pseudoaneur-
ysm bulge (14 patients, 53.8%), and bronchial compression
(12 patients, 46.20%). Although bronchial compression
was more frequent in those with ABFs, this finding also ap-
peared in some patients with an AEF without an ABF (50%
vs 37.5%, P ¼ .88).
Both active contrast extravasation and the ectopic gas
were present exclusively in thosewith AEFs. The identifica-
tion of active contrast extravasation was an ominous sign
for prognosis, with greater in-hospital mortality, but the dif-
ference did not reach statistical significance (33.3% vs
9.1%, P ¼ .32). In contrast, the presence of periaortic or
ectopic gas was associated with in-hospital mortality
(33.3% vs 0%, P ¼ .04).
Eleven patients (42.3%) did not undergo any surgical
(open or endovascular) treatment (6 with an ABF and 5
with an AEF). Nine patients were deemed not to be surgical
candidates, for either open or endovascular repair, because
of advanced malignancy, advanced age, and/or other severe
premorbid conditions. These patients’ life expectancy and
quality of life were so severely impaired by their associated
comorbidities that a conservative approach was selected.
The mean logistic EuroSCORE in this group of 9 patientsgery c December 2014
TABLE 3. Diagnostic test and CT scan findings
Characteristic
Overall
(n)
ABF
(n)
AEF
(n) P value
Diagnostic studies
CT scan 25 (96.2) 17 (94.4) 8 (100) .99
MDCT scan 18 (69.2) 10 (55.6) 8 (100) .03
Aortography 12 (46.2) 7 (38.9) 5 (62.5) .49
Gastrointestinal or
bronchial endoscopy
9 (34.6) 4 (22.2) 5 (62.5) .07
TEE 10 (38.5) 7 (38.9) 3 (37.5) .99
CT findings
Active extravasation 6 (23.1) 0 6 (75) <.001
Periaortic gas 5 (19.2) 0 5 (62.5) .001
Pseudoaneurysm bulge 14 (53.8) 10 (55.6) 4 (50) .99
Penetrating aortic ulcer 9 (34.6) 7 (38.9) 2 (25) .49
Intramural hematoma 17 (65.4) 11 (61.1) 6 (75) .81
Effacement of periaortic
or perigraft fat plane
8 (30.8) 1 (5.6) 7 (87.5) <.001
Esophagus wall thickening 4 (15.4) 0 4 (50) .005
Periprosthetic collection 4 (15.4) 2 (11.1) 2 (25) .75
Bronchial compression 12 (46.2) 9 (50) 3 (37.5) .55
Data in parentheses are percentages.CT, Computed tomography;ABF, aortobronchial
fistula; AEF, aortoesophageal fistula; MDCT, multidetector computed tomography;
TEE, transesophageal echocardiography.
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undergo surgery, 2 patients had been deemed surgical
candidates but died shortly before the surgery: a 21-
year-old man with a post-traumatic pseudoaneurysm and
an ABF who died of massive hemoptysis despite advanced
resuscitation techniques when being transferred to the oper-
ating room and a 72-year-old woman with a large thoracic
aorta aneurysm and an AEF who died of a massive hema-
temesis while waiting the arrival of a suitable thoracic aortic
endograft.
Fifteen patients (57.7%) underwent surgery (12 with
ABFs and 3 with AEFs). Of the 15 patients, 7 underwent
open surgery and 8 underwent TEVAR. The patients under-
going TEVAR were significantly older than those undergo-
ing open repair (65.2  6.4 years vs 51.7  11.5 years,
P ¼ .01). All the patients who underwent TEVAR, except
for 1, had been excluded from open repair because of pro-
hibitive comorbidities. Only the TEVAR group included
aortic fistulas caused by infection or malignancy. The TE-
VAR patients presented with a higher mean logistic Euro-
SCORE than the open surgery patients; however, this
difference did not reach statistical significance (33.6% 
20.4% vs 29.5%  20.2%, P ¼ .7).
In the patient with a simultaneous ABF and AEF, TEVAR
and bronchial stenting were used as a planned bridge to
definitive open repair. However, the patient died 5 days later
of septic shock before the open surgery stage of treatment.
The overall mean interval from diagnosis to surgery was
5.3  4.9 days.
Complications after open surgical repair occurred in 2
patients: paraparesis with subsequent complete recoveryThe Journal of Thoracic and Carin 1 and wound infection in 1. In the TEVAR group, 3 com-
plications occurred: catheter-related bacteremia in 1, respi-
ratory infection in 1, and fatal stroke (cause of death) in 1
patient.
All patients conservatively treated died during hospital
admission. In contrast, in-hospital mortality was 26.7% in
the surgical group (P< .001). Surgical operative deaths
occurred in 3 cases (37.5%) in the TEVAR group and 1
case (14.3%) in the open repair group. These 4 operative
deaths were caused by septic shock in 2 patients with
ABFs and 1 patient with simultaneous AEF and ABF and
by atheroembolic stroke in 1 patient with ABF.
The overall in-hospital mortality was 57.7% (n ¼ 15).
The overall mean expected in-hospital mortality predicted
by the logistic EuroSCORE was 43.6%  19.4%. The in-
hospital cause of death was septic shock in 7 patients, hem-
orrhagic shock in 5, and multisystem organ failure in 3. The
in-hospital mortality tended to be greater in those with AEF
than in those with ABF (75% vs 50%, P ¼ .44). No statis-
tically significant differences were found in in-hospital
mortality between primary and secondary fistulas (66.7%
vs 37.5%, P ¼ .33). The risk factors for in-hospital mortal-
ity were hemodynamic instability on admission (P ¼ .02),
sepsis (P ¼ .04), and nonoperative management (P<.001).
After hospital discharge, clinical and imaging follow-up
data were available for all surviving patients at a median
follow-up of 52.1  62.4 months. Overall survival esti-
mated using the Kaplan-Meier method, including early
mortality, was 37.8% at 1 year, 33.6% at 5 years, and
25.2% at 10 years. Survival for those with ABFs was
49.4% at 1 year, 43.2% at 5 years, and 32.4% at 10 years
(Figure 1). Survival for thosewith AEFs was 12.5% at 1 and
5 years; none of these patients had reached the 10-year
follow-up point at their latest follow-up visit (Figure 1). A
trend was seen toward greater long-term survival in the
ABF group (log-rank test, P ¼ .18; Figure 1).
The overall long-term survival for the surgical patients at
1 and 5 years was 66% and 58.7%, respectively. However,
those patients who had undergone open repair had an actu-
arial survival of 85.7% at 1 and 5 years compared with
long-term survival in the TEVAR group of 50% at 1 year
and 33.3% at 5 years (P ¼ .04; Figure 2).
Better long-term survival was recorded for those patients
who had presented with a secondary fistula, with 1- and 5-
year survival of 62.5% compared with 26.7% and 20% for
those who had presented with in a primary fistula, respec-
tively (P ¼ .08).
Regarding the etiology of the aortic fistulas, statistically
significant differences were found in long-term survival
(log-rank test, P ¼ .002). Patients with post-traumatic
ABFs or AEFs had the best long-term survival (100% at 1
and 5 years of follow-up, with only 1 late non–aortic-related
death). In contrast, theworst prognosiswas found among pa-
tients with fistula with an infectious origin, because none ofdiovascular Surgery c Volume 148, Number 6 3023
FIGURE 1. Cumulative survival for all aortic fistulas (n¼ 26), aortobronchial fistulas (ABF), and aortoesophageal fistulas (AEFs). Better survival was seen
for those with ABFs; however, this difference did not reach statistical significance. No deaths occurred after 3 months.
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due tomalignancies had the secondworst outcome,with sur-
vival of 25% at 1 year; no patients had survived to 2 years of
follow-up owing to the prognosis of their associated
malignancy.FIGURE 2. Survival stratified by surgical management type. The patients who
who had undergone thoracic endovascular aortic repair (TEVAR) (n ¼ 8; P ¼ .0
2-180; interquartile range, 100).
3024 The Journal of Thoracic and Cardiovascular SurNone of the 13 initial survivors developed any aortic-
related complications after hospital discharge. Three late
deaths occurred among the initial survivors. A 59-year-old
man, who had undergone open surgical repair of a primary
ABF due to a thoracic descending aorta aneurysm, died ofhad undergone open repair (n¼ 7) had greater long-term survival than those
4). The median follow-up of the surviving patients was 31 months (range,
gery c December 2014
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Dmyocardial infarction 10 years later. A 72-year-oldman died
of stroke 7 years after open repair of a secondary ABF. The
third late death resulted from brain metastasis in a 52-year-
old man who had previously undergone TEVAR for an AEF
caused by squamous cell esophageal cancer.
DISCUSSION
Despite either open or endovascular initial successful
management of aortic fistulas, preventing the patient’s
death by exsanguination, the results of the present series
have demonstrated that the mid- and long-term outcomes
are ultimately dependent on the etiology of the fistula.
Therefore, failure to treat the underlying cause will entail
a poor midterm outcome.
Contrast-enhanced CT, especially multidetector CT, has
been demonstrated to be a remarkably valuable diagnostic
tool for helping in the diagnosis of aortic fistulas.11-14 In a
review of the published data, MacIntosh and colleagues17
found a pseudoaneurysm at the fistula site in 73% of 63
cases of ABF. Pseudoaneurysms can result from local infec-
tion or mechanical stress on the anastomosis or graft wall
that causes tight adherence and pressure necrosis of the
bronchopulmonary or esophageal tissue.17 We had similar
results, finding an aortic pseudoaneurysm bulge at the site
of the fistula in 12 patients (50%).
Although hemorrhage of the aortic wall and pseudoa-
neurysm bulge were the most common radiologic findings
in our series, the presence of either active contrast extrava-
sation or ectopic gas was associated with a worse in-
hospital prognosis and was present only in those with
AEF. The presence of periaortic or ectopic gas was associ-
ated with in-hospital mortality (P ¼ .04).
In the published data, in-hospital mortality after open sur-
gery for ABF has been 15% to 25%17-21 but tended to be
even greater in those with AEF.1 The most frequently
used approach for open AEF repair has been left thoracot-
omy, followed by aortic replacement with a pros-
thetic17,18,20-22 or cryopreserved19,23 homograft or extra-
anatomic bypass in the case of severe mediastinal sepsis.20
In contrast, the 30-day mortality rate after ABF and AEF
endovascular repair has been reported to be 28% to 45%.8,9
Our results are comparable to those reported by other
investigators regarding surgical treatment of thoracic
aortic fistulas.8,9,21,23 In our series, the in-hospital mortality
in patients undergoing open repair was slightly lower than
that in the patients undergoing TEVAR; yet, that difference
was not statistically significant. However, TEVAR has been
performed on significantly older patients whose expected
in-hospital mortality tended to be higher, as determined
by the logistic EuroSCORE. Of the 7 patients who under-
went TEVAR, 5 had been considered unfit for open surgical
repair because of their high surgical risk, comorbidities,
and/or advanced age. Furthermore, only the TEVAR group
included those with aortic fistulas caused by infection orThe Journal of Thoracic and Carmalignancy. This is the underlying rationale for the greater
in-hospital mortality and lower actuarial survival observed
among those patients who had undergone endovascular
repair.
The incidence of ABF and AEF as a complication of pre-
vious TEVAR ranges from 2% to 3%. Eggebrecht and
colleagues2 reported an incidence of AEF after TEVAR of
1.9% and confirmed that all patients had died of fatal repeat
bleeding or mediastinitis. Jonker and colleagues8 published
a series of 11 aortic fistulas, with 2 cases secondary to
TEVAR (18.8%). More recently, Canaud and colleagues24
reported an incidence of aortic fistula as a complication of
TEVAR of 2.9% in a cohort of 236 patients. In our series,
1 case of ABF and 1 of AEF (7.7%) were secondary to
TEVAR. The patient sustaining an ABF was successfully
treated with a second TEVAR; however, the patient with
an AEF died of septic shock.
A medical conservative approach for those patients
deemed nonsurgical candidates led to 100% in-hospital
mortality in our series. This finding is similar to that
published by other investigators,20,25 who reported a fatal
outcome for those patients approached conservatively. We
found that nonoperative management is strongly related to
in-hospital mortality (P<.001), as well as other factors as
hemodynamic instability on admission (P¼ .02) and sepsis
(P ¼ .04).
Our results have highlighted that the etiology of the fis-
tula is of paramount importance in determining patients’
prognosis. In our series, all the patients with an aortic fistula
with an infectious cause died during hospitalization, and
those with an underlying malignancy as the main cause
also had a poor mid-term prognosis. In the published data,
in-hospital mortality for those with aortic fistulas secondary
to mycotic aneurysms or graft infections ranged from 25%
to 60%.4,8,26,27 In contrast, those caused by esophageal or
lung malignancies were associated with a mortality close
to 30%.9,27,28
In our series, post-traumatic fistulas showed great long-
term survival because, in those cases, aortic surgery alone
was curative. Those patients and those with fistulas caused
by ingestion of a foreign body or atherosclerotic aortic
pathology4,7-9 are the ideal candidates for endovascular
treatment. However, caution must be stressed because,
although the immediate and mid-term outcomes of TEVAR
have been encouraging,8,9 themajor concern is the durability
of this approach in the setting of a contaminated milieu
in the vicinity of foreign material. Despite appropriate
surgical treatment, most patients remain at high risk of
infectious complications, which were, unquestionably,
the most frequent cause of in-hospital death in our series
(7 patients). Other investigators have previously underlined
the importance of controlling infectious complications after
hemodynamically stabilizing the patient.8 TEVAR can
effectively serve as a bridge to definitive open surgery indiovascular Surgery c Volume 148, Number 6 3025
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patients severely compromised on hospital admission.8
In a multicenter study of 25 patients with ABF and/or
AEF,9 the investigators reported that of the 18 initial survi-
vors, 6 (33%) developed recurrent sepsis and/or hemor-
rhagic complications, resulting, in all cases, in death or
reintervention. More recently, Canaud and colleagues4 pub-
lished a review of the mid-term results of TEVAR in pa-
tients with ABFs. They identified 134 patients with ABF
who had been treated with TEVAR. Recurrence of the
ABF developed in 14 patients (11%), with a fatal outcome
in 50%. In our series, none of the 15 survivors from hospital
discharge developed aortic-related complications,
including recurrent sepsis.
Study Limitations
The present study had the limitations inherent to any
retrospective study. Although the patient population re-
flected the wide spectrum seen in clinical practice, it might
have lacked sufficient statistical power to determine with
confidence clinically important differences. Future studies
should incorporate data from a larger number of patients ac-
quired during a longer follow-up period to make definitive
conclusions on the effectiveness of, and indications for,
different surgical strategies.
CONCLUSIONS
The results of the present series have demonstrated that
mid- and long-term outcomes are ultimately dependent on
the etiology of the fistula. Therefore, failure to treat the un-
derlying cause will entail a poor mid-term outcome. Both
open and endovascular management of aortic fistula can
prevent death by exsanguination. TEVAR seems an attrac-
tive alternative for high-risk patients, especially as a bail-
out or bridging procedure. However, the Achilles heel of
aortic fistula management remains the difficulty in control-
ling the associated infection. Prolonged antibiotic therapy
and lifelong surveillance seem crucial for these patients,
regardless of the symptoms or clinical signs of sepsis.
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SELECTION CRITERIA
The selection criteria for open or endovascular treatment
was consistent among all the surgeons addressing thoracic
aortic disease and was in accordance with the institutional
protocol. The selection criteria were the patients’ hemody-
namic stability, comorbidities affecting life expectancy
and quality of life, and factors determining technical
feasibility.
The criteria for the primary intended treatment were not
consistent during the observation period of 15 years and
were modified by the incorporation of TEVAR using a mod-
ern risk–benefit evaluation and critical assessment of co-
morbidity status. Emergency (<24-hour) endovascular
aortic repair was available at our institution starting in
January 2003 owing to the need for an in-hospital stock of
thoracic aortic endografts.
FIGURE E1. The flowchart depicts the modification in patient treatment since the incorporation of emergency aortic endografting at our institution. In the
1998 to 2003 period, 1 patient had an aortoesophageal fistulas (AEF), whose primary intended treatment was urgent thoracic endovascular aortic repair
(TEVAR), but who had died waiting for the arrival of an appropriate size thoracic aortic stent-graft.
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TABLE E1. Isolated microorganisms and antibiotic therapies
Blood culture finding Antibiotic used
Staphylococcus aureus Daptomycin 6 mg/kg IV
every 24 h
Staphylococcus aureus Daptomycin 6 mg/kg IV
every 24 h
Staphylococcus aureus Vancomycin 1 g every 12 h
Staphylococcus aureus Vancomycin 1 g every 12 h
Staphylococcus epidermidis Meropenem 1 g IV every 8 h
Linezolid 600 mg IV
every 12 h
Staphylococcus epidermidis Vancomycin 1 g every 12 h
Gentamicin 1 mg/kg IV
every 8 h
Escherichia coli Imipenem-cilastatin 500 mg
IV every 6 h
Escherichia coli Imipenem-cilastatin 500 mg
IV every 6 h
Aspergillus fumigatus Amphotericin B 250 mg IV
every 24 h
Caspofungin 40 mg IV
every 24 h
Lifelong treatment with oral suppressive antibiotics was not performed in any case,
and antibiotic treatment was discontinued if no clinical, bacteriologic, or radiologic
evidence was found of ongoing sepsis. Our policy for antibiotic treatment involved
4 weeks of periprocedural intravenous antibiotics followed by case-specific admin-
istration of oral suppressive antibiotics according to the clinical and laboratory pa-
rameters of infection. However, our protocol for these patients has been highly
individualized. IV, Intravenously.
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